Ubiquitin-driven
molecular mechanisms
in cancer
Arbeitsgruppe Dr. Fernández-Sáiz
Research Interests
Ubiquitin is a small protein covalently linked to amino-acid residues of other polypeptides regulating protein homeostasis, localization and activation. Our lab focuses on the disclosure of the ubiquitinome controled by ubiquitin ligases and deubiquitinases (DUBs) with an emphasis on ubiquitylated proteins at the plasma membrane. We aim at studying ubiquitin molecular mechanisms that are deregulated in human diseases and often lead to tumor development, progression and clinical relapse. To adress these questions we integrate cutting edge protein biochemistry with preclinical models and patient samples in close collaboration with clinicians involved in the treatment of hematologic and lung malignancies. Our ultimate goal is to uncover new diagnostic biomarkers and innovative therapies for cancer treatment.
Heider M., Eichner R., Stroh J., Morath V., Kuisl A., Zecha J., Lawatscheck J., Baek K., Garz A.K., Rudelius M., Deuschle F.C., Keller U., Lemeer S., Verbeek M., Götze K.S., Skerra A., Weber W. A., Buchner J., Schulman B.A., Kuster B., Fernández-Sáiz V*. and Bassermann F*.
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
*Equal contribution.
Molecular Cell (6):1170-1186 (2021)
Eichner, R., Heider, M.*, Fernández-Sáiz, V.*, van Bebber, F., Garz, A.K., Lemeer, S., Rudelius, M., Targosz, B.S., Jacobs, L., Knorn, A.M., Slawska, J., Platzbecker, U., Germing, U, Langer, C., Knop, S., Einsele, H., Peschel, C., Haass, C., Keller, U., Schmid, B., Götze, K.S., Kuster, B., and Bassermann, F.
Immunomodulatory drugs disrupt the CRBN-CD147/MCT1 axis to exert anti-tumor activity and teratogenicity. (link is external)
Nature Medicine 22 (7):735-743 (2016) *Equal collaboration
Baumann, U.*, Fernández-Sáiz, V.*, Rudelius, M., Lemeer, S., Rad, R., Knorn, A.M., Slawska, J., Engel, K., Jeremias, I., Li, Z., Tomiatti, V., Illert, A.L., Targosz, B.S., Braun, M., Perner, S., Leitges, M., Klapper, W., Dreyling, M., Miething, C., Lenz, G., Rosenwald, A., Peschel, C., Keller, U., Kuster, B., and Bassermann, F.
Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. (link is external)
Nature Medicine, 2014. DOI: 10.1038/nm.3740. *Shared first authorship
Fernández-Sáiz, V.*, Targosz, B.-S.*, Lemeer, S., Eichner, R., Langer, C., Bullinger, L., Reiter, C., Slotta-Huspenina, J., Schroeder, S., Knorn, A.-M., Kurutz, J., Peschel, C., Pagano, M., Kuster, B. and Bassermann, F.
SCFFbxo9 directs the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promotes survival in multiple myeloma. (link is external)
Nat. Cell Biol. 2013. DOI: 10.1038/ncb2651. *Shared first authorship
Fernández-Sáiz, V. and Buchberger, A.
Imbalances in p97 cofactor interactions in human proteinopathy. (link is external)
EMBO Rep. 2010. DOI: 10.1038/embor.2010.49
Principal Investigator
Vanesa Fernández, PhD
Telefon 089 4140 9155
E-mail(link sends e-mail)
Klinikum rechts der Isar der TUM
Klinik und Poliklinik für Innere Medizin III - Hematology/Oncology (TranslaTUM)
Bau 522; 3. OG; Raum 22.3.6
Einsteinstr. 25
81675 München
Lab members (alphabetical order)
Eslam Katab, PhD candidate
E-Mail(link sends e-mail)
Former lab members
Jesús Urquiza, Practical ERASMUS+intership. Currently M.Sc. student at Complutense University, Madrid, Spain.
Join us!
Postdoc positions
If you are interested in doing a Postdoc in our lab, please contact Vanesa directly to discuss opportunities.
PhD, MD and M.Sc. student positions
We are looking for highly motivated students. Please contact Vanesa for inquiries for open PhD or MD student positions in the lab, as well as lab rotations for M.Sc. students.
Provide a CV and the contact information of a referee.
Contact(link sends e-mail)
Third party funding
DFG – Research Center SFB 1335
Yes Consortium(link is external)